| Literature DB >> 24750439 |
John D Johnston1, Peter Feldschreiber.
Abstract
Current European pharmaceutical legislation is not adequate to meet advances in science and technologies that will lead to rapid development of custom-made medicines. Using existing legislation for custom-made medical devices as a template and anti-sense oligonucleotides as model medicinal products, we propose new European pharmaceutical legislation to permit timely access to custom-made anti-sense oligonucleotide medicinal products. The proposals may be more widely applicable to other medicinal products.Entities:
Keywords: Europe; RNA; anti-sense oligonucleotide; custom-made medicine; personalized medicine; pharmaceutical regulation
Mesh:
Substances:
Year: 2014 PMID: 24750439 PMCID: PMC4093919 DOI: 10.1111/bcp.12250
Source DB: PubMed Journal: Br J Clin Pharmacol ISSN: 0306-5251 Impact factor: 4.335